Videos

Alice T. Shaw, MD, PhD, discusses the results of a trial looking at LDK378 for patients with ALK+ crizotinib-resistant non-small cell lung cancer.

Debu Tripathy, MD, from the Norris Comprehensive Cancer Center, discusses the treatment of breast cancer with anthracyclines and trastuzumab.

Neal D. Shore, MD, FACS, discusses patient considerations following treatment with radium-223 for bone metastases from prostate cancer.

Silvia Novello, MD, PhD, from the University of Turin, Italy, gives an overview of immunotherapy and the targeting of the MAGE-A3 protein in lung cancer.

Electra D. Paskett, PhD, Professor, College of Medicine, The Ohio State University, discusses screening for cervical cancer.

Lynn M. Schuchter, MD, describes two trials presented at the 2013 ASCO Meeting looking at nivolumab in patients with melanoma.

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses targeting the androgen receptor in breast cancer.

Jane Robertson, MD, Global Product Vice President at AstraZeneca, describes the mechanism of action of the PARP inhibitor olaparib.

Daniel H. Fowler, MD, senior investigator, Center for Cancer Research, National Cancer Institute, describes how T-rapa cells work.

Jane E. Churpek, MD, medical oncologist, hematologist, The University of Chicago, discusses the ATM, CHEK2, and PTEN genes in breast cancer.

Giorgio V. Scagliotti, MD, PhD, from the University of Turin, discusses recent advances in the molecular genotyping of patients with lung cancer.

Hope S. Rugo, MD, from the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses pathway changes in breast cancer.

Andrew T. Parsa MD, PhD, from the University of California, San Francisco, describes the administration of the prophage G-200 for recurrent glioblastoma multiforme.

Sandra Swain, MD, medical director of the Washington Cancer Institute at MedStar Washington Hospital Center, gives an overview of the next steps for pertuzumab in breast cancer.

D. Ross Camidge, MD, PhD, discusses the potential to utilize crizotinib as a treatment for patients with advanced non-small cell lung cancer who harbor a ROS1 gene rearrange

Cameron J. Turtle, MD, PhD, from the Fred Hutchinson Cancer Research Center, discusses the design of a chimeric antigen receptor (CAR).

Torsten O. Nielsen, MD, PhD, FRCPC, professor, pathology, University of British Columbia, discusses Ki67 in breast cancer.

Richard Finn, MD, from UCLA, discusses the treatment of patients with estrogen receptor-positive (ER+) breast cancer with antiestrogens.

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses PD-1 and PD-L1 in various cancers.

Robert Andtbacka, MD, from the University of Utah School of Medicine and Huntsman Cancer Institute, discusses a trial analyzing talimogene laherparepvec (T-VEC) in melanoma.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, UCLA, describes the development of cyclin-dependent kinases (CDKs) for the treatment of cancer.

Andre Goy, MD, from John Theurer Cancer Center, discusses recent research into fighting cancer with the immune system.

Suresh S. Ramalingam, MD, from the Winship Cancer Institute, discusses the investigation of the heat shock protein 90 inhibitor ganetespib as a treatment for patients with advanced lung cancer.

Marcia Brose, MD, PhD, from the University of Pennsylvania, on repurposing drugs to treat thyroid cancer.

Krishnansu S. Tewari, MD, from the University of California, Irvine, comments on the next steps for bevacizumab for recurrent cervical cancer.

Clifford A. Hudis, MD, describes ASCO's CancerLinQ program, which is a direct response to the Insitute of Medicine's call for rapid learning systems.

Richard D. Carvajal, MD, describes the design of a phase II study of selumetinib versus temozolomide in gnaq/Gna11 mutant uveal melanoma.

Emiel J. Rutgers, MD, from the Netherlands Cancer Institute, describes the personalization of treatment for patients with early-stage breast cancer.

Jane E. Churpek, MD, describes the BROCA genetic assay, uses targeted genomic capture and next-generation sequencing to analyze a panel of 42 genes.

Howard L. Kaufman, MD, Rush University Medical Center, comments on the changing outlook for immunotherapies.